[Skip to Content]
[Skip to Content Landing]
Views 939
Citations 0
Invited Commentary
August 8, 2019

Factors to Consider When Contemplating Posttreatment Surveillance for Survivors of HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Author Affiliations
  • 1Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland
JAMA Otolaryngol Head Neck Surg. 2019;145(10):908-910. doi:10.1001/jamaoto.2019.1976

In this issue of JAMA Otolaryngology–Head & Neck Surgery, Masroor at al1 explore the outcomes associated with adherence to the current National Comprehensive Cancer Network (NCCN) posttreatment surveillance recommendations for patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC).2 Recognition of the favorable prognosis of HPV-associated OPSCC has led to the issue of whether the current NCCN-guided surveillance recommendations are appropriate for survivors of HPV-associated OPSCC. The goals of a regular surveillance schedule are to identify cancer recurrence and sequelae of therapy. To our knowledge, no study to date has evaluated the benefit of a surveillance schedule specific to HPV-associated OPSCC.

×